Arrowhead Pharmaceuticals Inc ARWR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran
-
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
-
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran
-
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases
-
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
Trading Information
- Previous Close Price
- $18.85
- Day Range
- $18.68–19.27
- 52-Week Range
- $18.15–39.65
- Bid/Ask
- $18.85 / $18.83
- Market Cap
- $2.34 Bil
- Volume/Avg
- 669,491 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 110.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 525
- Website
- https://www.arrowheadpharma.com
Comparables
Valuation
|
Metric
|
ARWR
|
UTHR
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 14.90 | — |
Price/Book Value | 7.08 | 2.73 | 3.80 |
Price/Sales | 110.81 | 6.58 | — |
Price/Cash Flow | — | 14.11 | — |
Price/Earnings
ARWR
UTHR
RCKT
Financial Strength
|
Metric
|
ARWR
|
UTHR
|
RCKT
|
|---|---|---|---|
Quick Ratio | 4.49 | 3.92 | 7.42 |
Current Ratio | 4.65 | 4.35 | 7.79 |
Interest Coverage | −23.73 | 22.67 | −143.43 |
Quick Ratio
ARWR
UTHR
RCKT
Profitability
|
Metric
|
ARWR
|
UTHR
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −58.98% | 16.95% | −41.09% |
Return on Equity (Normalized) | −147.41% | 20.53% | −46.72% |
Return on Invested Capital (Normalized) | −105.66% | 16.62% | −47.69% |
Return on Assets
ARWR
UTHR
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rxnmpwry | Szgz | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wzszjbj | Nvnwvh | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rkvmztj | Yzzdp | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gqdhgqwv | Lpjcpl | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Psxrlxz | Wmwn | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cmfsjwpr | Ddcl | $28.5 Bil | |||
| Moderna Inc
MRNA
| Zmzpsnly | Ppkrz | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Rftqckyx | Kyfbt | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vwcfyspx | Vfvlsft | $13.0 Bil | |||
| Incyte Corp
INCY
| Fprbfsbl | Dchnpy | $12.9 Bil |
United States